RO7017773 for Autism Spectrum Disorder
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called RO7017773 to see if it can help people aged 15-45 with Autism Spectrum Disorder (ASD) who have a certain level of intelligence. The study will check how well the drug works, how safe it is, and how the body handles it.
Will I have to stop taking my current medications?
The trial requires that your current treatment regimens be stable for 8 weeks before screening and remain stable during the study. If you are taking any prohibited medications or herbal remedies, you must stop them at least 6 weeks before randomization.
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for individuals aged 15-45 with Autism Spectrum Disorder (ASD), who score at least 50 on the WASI-II intelligence test, have a BMI of 18.5 to 40 kg/m2, and experience autism symptoms. Participants must have a supportive caretaker and be able to follow study procedures without undue risk.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either placebo or a fixed dose of RO7017773 for approximately 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- RO7017773
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University